Table 5 Predictors of culture conversion at 2 months in the patients with MDR/RR/pre-XDR-TBTB.

From: Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Characteristic

Unadjusted OR (95% CI)

P value

Adjusted OR (95% CI)

P value

Age

1.003 (0.963, 1.044)

0.884

  

BMI < 18.5 kg/m2

0.733 (0.286, 1.883)

0.519

  

Male

1.403(0.585, 3.365)

0.447

  

Ever smoker

0.580 (0.200, 1.684)

0.317

  

Diabetes mellitus

0.379 (0.069, 2.078)

0.264

  

TB treatment history

2.615 (0.883, 7.741)

0.083

0.509

Positive AFB smear at treatment initiation

0.562 (0.230, 1.376)

0.207

  

Imagining features

    

 Lung damage

1.235 (0.377, 4.048)

0.727

  

 Pulmonary atelectasis

0.367 (0.146, 0.918)

0.032

0.437

 Cavity

1.187 (0.484, 2.910)

0.708

  

 Bilateral disease

0.971 (0.326, 2.889)

0.957

  

 Subtypes of TBTB

    

 Inflammatory infiltration

1.033 (0.390, 2.739)

0.947

  

 Ulceration necrosis

0.754 (0.305, 1.867)

0.542

  

 Granulation hyperplasia

1.029 (0.303, 3.496)

0.964

  

 Cicatrices stricture

1.344 (0.490, 3.692)

0.566

  

Multiple bronchi involvedunder bronchoscopy

0.529 (0.220, 1.275)

0.156

0.077

Tracheobronchial stenosis under bronchoscopy

0.260 (0.090, 0.758)

0.014

0.087

Tracheobronchial obstructionunder bronchoscopy

0.729 (0.229, 2.322)

0.592

  

Treatment

    

 Treatment with bedaquiline

5.431 (2.025, 14.567)

0.001

13.417 (4.067, 44.260)

< 0.001

 Treatment with delamanid

2.483 (0.830, 7.423)

0.104

9.333 (2.498, 34.878)

0.001

 Treatment with any FQ

0.347 (0.124, 0.972)

0.044

0.982

 Treatment with linezolid

1.464 (0.520, 4.118)

0.470

0.082

 Treatment with SLID

0.573 (0.233, 1.408)

0.224

0.685

 Interventional therapy

1.028 (0.274, 3.854)

0.968

0.696

 Surgical resection

0.325 (0.032, 3.260)

0.339

0.681

  1. AFB acid-fast bacilli, BMI body mass index, CI confidence interval, DST drug susceptibility testing, FQ fluoroquinolone, HIV human immunodeficiency virus, OR odds ratio, SLID second-line injectable drug.